Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
General Information
NCT#: NCT03535727
Study ID: J1847
Trial Phase: Phase I/II
Trial Sponsor: Johns Hopkins University
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Capecitabine, Irinotecan, Cisplatin, GAX-CI